Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that compounded topical minoxidil was associated with higher adherence, fewer side effects, and more clinical improvement in Black women compared to over-the-counter minoxidil.

This study found that while the over-the-counter market for minoxidil hair loss products is expanding, only 25% of these products report safety information, and none report adverse effects, highlighting a need for greater transparency and accuracy in their advertising.

This study conducted on YouTube Shorts videos found that a majority of content related to alopecia recommended treatments that could be carried out independently, such as over-the-counter medications, while professional recommendations by dermatologists comprised less than 15% of the videos but showed high viewer engagement.

This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

This meta-analysis found that among topical OTC treatments for male androgenetic alopecia, minoxidil 5% applied twice daily was the most effective in increasing total hair density over 24 weeks.

This study reviews popular over-the-counter hair loss products available online but reports no new clinical results.

This guideline summary, endorsed by six Spanish pediatric societies, outlines consensus recommendations for managing childhood asthma, emphasizing diagnosis, maintenance treatment with low-dose inhaled corticosteroids, and patient education for effective control.

This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.

In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.

This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This study found that the TrichoScan effectively measures hair growth changes, showing significant increases in hair counts and thickness in men with androgenetic alopecia after 6 months of using 5% minoxidil solution.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.

This study found that cationic vesicles enhanced minoxidil skin retention and in vivo hair growth efficacy compared to other formulation types due to electrostatic interactions with the skin.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

This review discusses the emerging pathophysiological factors and potential new therapies for androgenetic alopecia beyond traditional treatments, but reports no new results.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

Cyclosporin and minoxidil promote hair growth.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

This study found that a dietary supplement containing L-cystine, medicinal yeast, and pantothenic acid significantly improved hair growth in women with telogen effluvium over six months compared to placebo.

This study found that a combination of 5% hexane extract of Curcuma aeruginosa and 5% minoxidil slowed hair loss and increased hair growth in men with androgenetic alopecia.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

This study analyzed trends in consumer and physician interest in nonsurgical hair loss therapies, finding that internet searches for treatments like minoxidil and low-level laser therapy increased over time, influenced by regulations and social media.

Prescription and alternative therapies for hair loss will be compared for effectiveness.

This review highlights various alternative and complementary treatments for androgenic alopecia, noting that while only two FDA-approved options exist, increased awareness among dermatologists of supportive evidence for other therapies may better inform patient education.

This article highlights the need to consider topical minoxidil as a differential diagnosis for unexplained headache and dizziness due to its potential side effects.

In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.

In this study, a case was reported where oral Minoxidil led to severe ocular complications, specifically Central Retinal Vein Occlusion and Cilioretinal Artery Occlusion, resulting in sudden vision loss which improved upon discontinuation.